| 89.27 BATS BZX Real-Time Price As of 1:52pm ET |  +2.32 / +2.67%Today’s Change | 72.30 Today|||52-Week Range 94.19 | +6.32% Year-to-Date |
| Gilead's Vemlidy Gets Approval in China for HBV Infection Nov 20 / Zacks.com - Paid Partner Content | Roche's Tecentriq Gets Priority Review for Breast Cancer Nov 14 / Zacks.com - Paid Partner Content |
| Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta Nov 19 / Zacks.com - Paid Partner Content | Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe Nov 13 / Zacks.com - Paid Partner Content |
| Drug Pricing Resurfaces, Pfizer to Raise Cost of 41 Drugs Nov 19 / Zacks.com - Paid Partner Content | Tilray (TLRY) to Report Q3 Earnings: What's in the Cards? Nov 12 / Zacks.com - Paid Partner Content |
| The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX and Deere Nov 15 / Zacks.com - Paid Partner Content | Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View Nov 09 / Zacks.com - Paid Partner Content |
| Previous close | 86.95 |
| Today’s open | 87.94 |
| Day’s range | 87.77 - 89.35 |
| Volume | 119,683 |
| Average volume (3 months) | 2,241,147 |
| Market cap | $200.9B |
| Earnings growth (last year) | +17.07% |
| Earnings growth (this year) | +9.27% |
| Earnings growth (next 5 years) | +8.00% |
| Revenue growth (last year) | +1.88% |
| P/E ratio | 15.6 |
| Price/Sales | 4.03 |
| Price/Book | 2.72 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRKMerck | +0.05 | +0.07% |
| PFEPfizer | -0.37 | -0.85% |
| ABBVAbbVie | -2.07 | -2.35% |
| ABTAbbott Laboratories | -0.03 | -0.05% |
| Next reporting date | January 30, 2019 |
| EPS forecast (this quarter) | $1.31 |
| Annual revenue (last year) | $49.4B |
| Annual profit (last year) | $7.7B |
| Net profit margin | 15.69% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Vasant Narasimhan |
Chief Financial Officer Harry Werner Kirsch |
Corporate headquarters Basel, Basel-stadt (basle Town) |
